

Results from an ongoing phase II study of isolated abdominal perfusion for chemoresistant and recurrent ovarian cancer

Favorable study results of regional chemotherapy for recurrent ovarian cancer presented at the 38th Congress of the European Society of Surgical Oncology


BURGHAUSEN, GERMANY, October 23, 2018 /EINPresswire.com/ -- Medias Klinikum GmbH & Co KG, a private hospital specialized in surgical oncology, focusing on the treatment of primary and metastatic solid tumors, announces that the results from an ongoing phase II study of regional chemotherapy in terms of hypoxic isolated abdominal perfusion with chemofiltration (HAP-F) for chemoresistant and recurrent ovarian cancer, have been presented at the

38th [Congress of the European Society of Surgical Oncology \(ESSO\)](#) and BASO - the Association for Cancer Surgery. The study, Isolated hypoxic abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer: experience in 143 platinum-refractory and 25 chemo-naïve ovarian cancer patients, was conducted by Professor Dr. Karl R. Aigner, one of the world's most experienced experts in the field of regional chemotherapy, and his group. In 1981, he developed the technique of isolated liver perfusion and was the first physician worldwide performing this method in humans using a heart-lung machine.

An abstract of the presented data is published under the abstract number ESSO38-0273 in the abstract book of the Journal of the European Society of Surgical Oncology (EJSO).

Commenting on the announcement, Professor Dr. Karl R. Aigner, Head of the Department of Surgical Oncology at Medias Klinikum, said, "Increased dose or dose-dense chemotherapy for platinum-refractory ovarian cancer is limited because of increasing toxicity. In order to break through drug resistance and reduce toxicity, augmented drug exposure was administered only to the abdomen by means of an isolated perfusion system with extracorporeal circuit. Toxicity and side-effects were generally low due to subsequent chemofiltration". The preliminary results of the study presented at the 38th Congress of the European Society of Surgical Oncology (ESSO) this year, showed that HAP-F for patients with chemoresistant and recurrent FIGO stage IIIC and IV ovarian cancer, is an effective treatment modality that breaks through drug resistance, with encouraging survival data and considerable, but not only, for patients who have no other treatment options due to chemoresistance.

[About Medias Klinikum](#), Department of Surgical Oncology



Medias Klinikum is a private clinic located in Burghausen (Bavaria), Germany specialized in regional chemotherapy (RCT), a targeted treatment modality for primary and metastatic tumors that is highly concentrated, regional, and less toxic. We have more than 35 years of expertise in this special field of surgical oncology. Prof. Dr. med. Aigner, the medical director of the clinic, is one of the world's most experienced experts in this treatment method. He has given numerous lectures on RCT and performed guest operations in the most renowned institutions in the USA, Japan, China, Israel, Egypt, Australia and a number of other countries. In 1981, Professor Aigner developed a technique for performing the first isolated liver perfusion in humans using a heart-lung machine, and over subsequent years a variety of additional surgical procedures and specialized catheters for isolated therapy of organs and parts of the body, including the treatment of pancreatic carcinoma.

Public Relations

Medias Klinikum GmbH & Co KG

+49867791600

[email us here](#)

Visit us on social media:

[Facebook](#)

[Google+](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.